Nuclear Medicine & Positron Emission Tomography

In our early days, we imported the CTI RDS III medical cyclotron and our first PET scanner for oncology imaging and neurological assessments for conditions such as autism and Parkinson's disease. In early 2000s, we introduced the groundbreaking PET/CT scan technology, and became the only non-FDG production centre in Hong Kong with all the technical expertise to synthesise radiotracers tagged with fluorine-18, carbon-11, nitrogen-13, targeting specific clinical needs in oncology, neurology and cardiology imaging. Widely used in diagnosing certain types of cancer and neurologic diseases, some of these tracers are too short-lived for transportation, i.e. only 20 minutes or less. Therefore, patients from other local and overseas medical institutions are often referred to us for comprehensive imaging and patient management. 

While some centres are now experimenting with tracer production, we, as the pioneer in local PET/CT services for more than 20 years, maintain a solid lead with continuous knowledge acquisition and equipment upgrades to offer the most reliable and all-round clinical services to our patients.

Our clinical services include Positron Emission Tomography/Computed Tomography (PET/CT), Nuclear Medicine (NM), Radionuclide Therapy (RNT) and Radiopharmaceutical dispensing services. Unlike other centres, our Nuclear Medicine Specialists provide consultation to ensure the provision of effective and personalised services based on each patient’s clinical needs. 

In view of the growing clinical demand, we continue to expand our molecular imagining service with the latest technology and facilities, including 4 on-site medical cyclotrons, 2 radiopharmacy laboratories, a QC laboratory, 4 Positron Emission Tomography/Computed Tomography (PET/CT) scanners, 2 Single Photon Emission Computed Tomography (SPECT/CT) scanners and a dedicated SPECT cardiac camera. 

In addition to diagnostic services, we have also incorporated a unique facility to provide a full spectrum of Radionuclide Therapy services for cancers and metabolic diseases. The current service scope includes Iodine-131 for thyrotoxicosis, Iodine-131 for thyroid cancer ablation, Iodine-131 MIBG and Lutetium-177 with DOTA-Conjugated peptides for neuroendocrine tumor, Lutetium-177 PSMA for prostate cancer, Lu-177 FAPI for cancer-associated fibroblasts, Radium-223 Dichloride for bone metastases of prostate cancer and Yttrium-90 Microspheres for liver tumours. 

We are committed to high safety and reliability in the manufacture of PET radiopharmaceuticals and radiotracers. Our Radiopharmacy and Quality Control Laboratories are well-recognised for our exceptional techniques and equipment. The facility is fully licensed by the Department of Health of the Government of HKSAR for production and sales of PET tracers; accredited by the Australian Council on Healthcare Standards (ACHS); and with HKSH Comprehensive Oncology Centre, certified by the National Medical Products Administration (NMPA) as the only private medical institution in Hong Kong to conduct clinical trials for human used drugs. With more than 20 years of experiences and unparalleled expertise, the team proactively sources the latest and most useful radiopharmaceuticals around the world for importation to Hong Kong. We also supply PET tracers to other local clinical centres, indicating that we are fully trusted and affirmed by the community.